Theinfluenzavaccinefieldhasbeenconstantlyevolvingtoimprovethespeed,scalability,andflexibilityofmanufacturing,and
improvethebreadthandlongevityoftheprotectiveimmuneresponseacrossagegroups,givingrisetoanarrayofnextgenerati
vaccinesindevelopment.Amongthese,therecombinantinfluenzavaccinetetravalent(RIV4),usingabaculovirusexpressionvec
systemtoexpressrecombinanthaemagglutinin(r HA)ininsectcells, istheonlyonetohavereachedthemarketandhasbeen
studiedextensively. Wedescribehowtheuniquestructuralfeaturesofr HAin RIV4improveprotectiveimmuneresponsescompa
toconventionalinfluenzavaccinesmadefrompropagatedinfluenzavirus.Inadditiontothesequenceintegrity,characteristic
recombinantproteins, uniquepost-translationalprocessingofther HAininsectcellsinstillsfavourabletertiaryandquaternary
structuralfeatures. Theabsenceofprotease-drivencleavageandadditionofsimple N-linkedglycanshelptopreserveandexp
certainconservedepitopeson HAmolecules, whicharelikelyresponsibleforthehighlevelsofbroadlycross-reactiveandprotect
antibodieswithrarespecificitiesobservedwith RIV4. Furthermore, thepresenceofuniformcompact HAoligomersandabsence
eggproteins, viral RNAorprocessimpurities, typicallyfoundinconventionalvaccines, areexpectedtoeliminatepotentialadve
reactionstothesecomponentsinsusceptibleindividualswiththeuseof RIV4. Thesedistinctstructuralfeaturesandpurityoft
recombinant HAvaccinethusprovideanumberofbenefitsinvaccineperformancewhichcanbeextendedtootherviraltarg
suchasfor COVID-19.